Protein aggregation plays a key role in the control of many physiological systems.
Our current primary interest is in aggregation of a class of proteins known as amyloidogenic proteins. This detailed analysis at the molecular level is critical in order to establish the role of aggregation in the toxic response, and to develop rational strategies for therapeutic intervention. Targeted drug technology is the other primary focus of my group. We are specifically interested in improving the efficacy of immunotoxins and related molecules for cell-specific killing. In one project, we are studying the kinetic pathways for cellular processing of antibody-toxin conjugates.